Safety and Efficacy in Relapsed or Refractory Classic Hodgkin’s Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials

Table 3

The pooled response rate.

		Data points	No.	Event rate	95% CI	Heterogeneity
						I ^2 (%)	for I^2
ORR		14	731	0.74	0.70–0.79	54.0	<0.01
CR		14	731	0.24	0.18–0.34	84.0	<0.01
PR		14	731	0.48	0.41–0.55	73.0	<0.01
SD		13	723	0.15	0.12–0.17	12.0	0.32
PFS	6-mo	6	521	0.76	0.72–0.79	5.0	0.38
	1-y	2	111	0.59	0.50–0.68	38.0	0.21
OS	6-mo	5	438	0.99	0.98–1.00	22.0	0.28
	1-y	5	297	0.93	0.90–0.96	0.0	0.61